Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Herpes

Herpes

Herpes simplex type 1 (HSV‑1) is a widespread pathogen responsible for orolabial lesions. It is an enveloped, double-stranded DNA (dsDNA) virus belonging to the family Herpesviridae. Once the virus infects a host cell, its double‑stranded DNA genome is delivered into the nucleus, where a coordinated cascade of immediate‑early, early, and late gene expression directs viral DNA replication, structural protein synthesis, and virion assembly. After primary infection of epithelial cells, HSV-1...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Genital Herpes

Genital Herpes

Genital herpes is a sexually transmitted infection primarily caused by herpes simplex virus type 2 (HSV-2), though herpes simplex virus type 1 (HSV-1) is increasingly implicated in genital infections, particularly among younger populations. Transmission occurs mainly through sexual contact, with asymptomatic viral shedding serving as a major route of spread. This characteristic makes HSV-2 difficult to control at a population level, as individuals may unknowingly transmit the virus even in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A multi-institutional report of children with atypical teratoid rhabdoid tumor treated with intensive multimodal therapy.

Neuro-oncology practice·2026

Same author

Oncolytic viruses enhance CAR-T activity for the treatment of pediatric diffuse midline gliomas.

Molecular therapy. Oncology·2026

Same author

BTK inhibition enhances immunovirotherapy in glioblastoma via tertiary lymphoid structure modulation.

bioRxiv : the preprint server for biology·2026

Same author

Impact of Distance From the Isocenter on Local Control and Toxicity for Zero Margin, Single-Isocenter Multitarget Volumetric Modulated Arc Therapy-Based Stereotactic Radiosurgery for Brain Metastases.

International journal of radiation oncology, biology, physics·2026

Same author

Outcomes following radiotherapy for atypical teratoid/rhabdoid tumor in combination with surgery and intensive chemotherapy: A report from Children's Oncology Group study ACNS0333.

Neuro-oncology pediatrics·2026

Same author

AEGIS reveals epitope- and clone-resolved convergence of CNS B and T cell autoreactivity in ROHHAD.

bioRxiv : the preprint server for biology·2026

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Herpes simplex virus oncolytic therapy for pediatric malignancies.

Gregory K Friedman¹, Joseph G Pressey, Alyssa T Reddy

¹Department of Pediatrics, Children's Hospital of Alabama, University of Alabama at Birmingham, USA. gfriedman@peds.uab.edu

Molecular Therapy : the Journal of the American Society of Gene Therapy

|April 16, 2009

Summary

Oncolytic herpes simplex virus (HSV) offers a promising new treatment for pediatric cancers resistant to traditional therapies. Further research is needed to overcome challenges before clinical application in children.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

Related Experiment Videos

Last Updated: Jun 24, 2026

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

Area of Science:

Oncology
Virology
Pediatric Medicine

Background:

Pediatric cancer survival rates are improving, yet some children develop treatment-resistant disease.
Traditional therapies like surgery, chemotherapy, and radiation are ineffective for a subset of pediatric cancers.
Novel therapeutic strategies are essential for managing difficult-to-treat pediatric malignancies.

Purpose of the Study:

To review the potential benefits of oncolytic herpes simplex virus (HSV) therapy for pediatric solid tumors.
To discuss the application of HSV therapy in challenging pediatric cancers such as brain tumors, neuroblastomas, and sarcomas.
To identify the challenges hindering the translation of oncolytic HSV therapy from laboratory research to clinical practice in pediatric patients.

Main Methods:

Literature review of oncolytic herpes simplex virus (HSV) therapy.
Analysis of existing research on HSV in pediatric oncology.
Identification of challenges in clinical translation for pediatric populations.

Main Results:

Oncolytic herpes simplex virus (HSV) demonstrates promise as a targeted therapy for pediatric cancers.
Potential applications include brain tumors, neuroblastomas, and sarcomas.
Significant challenges remain in advancing HSV therapy for pediatric use.

Conclusions:

Oncolytic HSV therapy represents a potential advancement for pediatric malignancies unresponsive to conventional treatments.
Addressing challenges is crucial for successful clinical implementation in pediatric patients.
Further research and development are required to realize the full potential of HSV-based cancer therapies in children.